Enanta Pharmaceuticals Starts Clinical Trial of Antibiotic for Drug Resistant Bacteria

Xconomy Boston — 

Enanta Pharmaceuticals, a Watertown, MA-based developer of anti-infection drugs, said today it has started an early stage clinical of an oral antibiotic for drug-resistant bacteria. The drug, EDP-322, is being tested for hospital and community-acquired infections, including drug-resistant MRSA. In previous animal tests, the drug showed activity against MRSA strains that resist other potent antibiotics like vancomycin, Pfizer’s Zyvox, and Cubist Pharmaceuticals’ Cubicin.